Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$11.12 - $22.2 $166,800 - $333,000
15,000 New
15,000 $171,000
Q4 2020

Feb 10, 2021

SELL
$35.35 - $50.67 $707,000 - $1.01 Million
-20,000 Reduced 28.57%
50,000 $3,000
Q3 2020

Nov 16, 2020

BUY
$35.98 - $47.66 $2.52 Million - $3.34 Million
70,000 New
70,000 $10,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $684M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Bluefin Capital Management, LLC Portfolio

Follow Bluefin Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bluefin Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bluefin Capital Management, LLC with notifications on news.